

Maria Teresa Petrucci

Maria Teresa Petrucci è Dirigente Medico presso l'Ematologia dell'Azienda Policlinico Umberto I, Dipartimento di Biotecnologie Cellulari ed Ematologia Università Sapienza di Roma. Dopo aver conseguito la laurea in Medicina e Chirurgia e la Specializzazione in Ematologia presso la Sapienza Università di Roma, ha completato il suo percorso di formazione negli Stati Uniti prima presso l'Università dell'Arkansas "Medical Sciences" di Little Rock, e successivamente presso la "New York University Medical Center and Kaplan Comprehensive Cancer Center" di New York. Ha conseguito un MASTER in "Management dei Servizi Sanitari applicati all'Ematologia" presso l'ISTUD di Stresa. È uno dei membri del board del Gruppo Italiano sullo Studio del Mieloma e di società scientifiche italiane, quali la Società Italiana di Ematologia (SIE), la Società Italiana di Ematologia Sperimentale (SIES) e la Società Italiana di Amiloidosi (SIA), e internazionali, come la Società Americana di Ematologia (ASH) e la Società Internazionale di Amiloidosi (ISA). Ha pubblicato numerosi lavori e contribuito alla stesura di diversi libri. La sua area di maggior interesse riguarda le Discrasie Plasmacellulari con particolare riguardo allo studio di fattori diagnostici e prognostici di pazienti affetti da Mieloma Multiplo. Valutazione clinica dell'efficacia di nuovi farmaci utilizzati nell'ambito di protocolli terapeutici internazionali. Diagnostica e terapia dell'amiloidosi AL e della Macroglobulinemia di Waldenstrom. La particolare attenzione alle esigenze dei pazienti, ha contribuito al suo interesse nell'organizzare e partecipare a seminari dedicati ai pazienti e ai loro familiari. E' coinvolta in numerosi studi clinici terapeutici, nazionali e internazionali, che permettono di utilizzare, con notevole anticipo rispetto alla registrazione, nuove molecole nel trattamento dei pazienti.

Curriculum vitae >>

Elenco Pubblicazioni

1. Pisani F, Petrucci MT, Giannarelli D, Bongarzone V, Montanaro M, De Stefano V, La Verde G, Gentilini F, Levi A, Za T, Moschetti A, Annino L, Petti MC. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. *J Exp Clin Cancer Res.* 31:17;2012
2. Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. *J Mol Med (Berl).* 90(10):1133-44; 2012
3. Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. *120(1):9-19; 2012*
4. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015

- Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med.* 10:1759-69;2012
5. Cartoni C, Brunetti GA, Federico V, Efficace F, Grammatico S, Tendas A, Scaramucci L, Cupelli L, D'Elia GM, Truini A, Niscola P, Petrucci MT. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. *Support Care* 20:2621-6;2012
 6. Gentilini F, Levi A, Federico V, Russo E, Foà R, Petrucci MT. Bortezomib a safe treatment for patients with multiple myeloma and cystic fibrosis. *Mediterr J Hematol Infect Dis.* May 7;2012.
 7. Federico V, Breccia M, Petrucci MT, Loglisci G, Mansueto G, Mercanti C, Levi A, Cartoni C, Musto P, Alimena G. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma. *Clin Adv Hematol Oncol.* 10:266-8;2012
 8. Rago A, Grammatico S, Za T, Levi A, Mecarocci S, Siniscalchi A, De Rosa L, Felici S, Bongarzoni V, Piccioni AL, La Verde G, Pisani F, Franceschini L, Paviglianiti AL, Caravita T, Petrucci MT, De Stefano V, Cimino G; on behalf of the Multiple Myeloma GIMEMA-Latium Region Working Group. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form. *Cancer.* 118:5544-9;2012
 9. Andriani A, Petrucci MT, Caravita T, Montanaro M, Villivà N, Levi A, Siniscalchi A, Bongarzoni V, Pisani F, De Muro M, Coppetelli U, Avvisati G, Zullo A, Agrillo A, Gaglioti D. Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study. *Blood Cancer J.* Mar 23;2012
 10. Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, Tuana G, Lionetti M, Bonaparte E, Sirchia SM, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omedè P, Boccadoro M, Palumbo A, Neri A. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. *Am J Hematol.* 88:16-23;2013
 11. Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C, Leonetti F, Casato M, Pergolini M, Petrucci MT, Cruccu G. Peripheral nociceptor sensitization mediates allodynia in patients with distal symmetric polyneuropathy. *J Neurol.* 260:761-6;2013
 12. Petrucci MT, Levi A, Bringham S, Scotti S, Gentilini F, Russo S, Siniscalchi A, Larocca A, Grammatico S, Boccadoro M, Foà R, Palumbo A. Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: A multicenter, open label phase 1/2 study. *Cancer.* 119:971-7;2013
 13. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG. Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. *J Clin Oncol.* 31:448-55;2013
 14. Za T, De Stefano V, Rossi E, Petrucci MT, Andriani A, Annino L, Cimino G, Caravita T, Pisani F, Ciminello A, Torelli F, Villivà N, Bongarzoni V, Rago A, Betti S, Levi A, Felici S, Gentilini F, Calabrese E, Leone G; the Multiple Myeloma GIMEMA-Latium Region Working Group. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. *Br J Haematol.* 160:673-9;2013

15. Dimopoulos MA, Delforge M, Hajek R, Kropff M, Petrucci MT, Lewis P, Nixon A, Zhang J, Mei J, Palumbo A. Lenalidomide, melphalan, and prednisone followed by lenalidomide maintenance improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. *Haematologica*. 98:784-8;2013
16. Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Bladé J. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. *Br J Haematol*. 160:649-59;2013
17. Todoerti K, Agnelli L, Fabris S, Lionetti M, Tuana G, Mosca L, Lombardi L, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Omedè P, Tassone P, Boccadoro M, Palumbo A, Neri A, Musto P. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. *Clin Cancer Res*. 19:3247-3258;2013
18. Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, Tuana G, Mosca L, Gallo Cantafio ME, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omede P, Morabito F, Tassone P, Boccadoro M, Palumbo A, Neri A. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. *Clin Cancer Res*. 19:3130-3142;2013
19. Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT, Santoni A, Cippitelli M. Inhibition of Glycogen Synthase Kinase-3 Increases NKG2D Ligand MICA Expression and Sensitivity to NK Cell-Mediated Cytotoxicity in Multiple Myeloma Cells: Role of STAT3. *J Immunol*. 190:6662-72;2013
20. Moschella F, Torelli GF, Valentini M, Urbani F, Buccione C, Petrucci MT, Natalino F, Belardelli F, Foà R, Proietti E Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy. *Clin Cancer Res*.19:4249-61;2013
21. Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedè P, Montefusco V, Petrucci MT, Giuliani N, Passera R, Pietrantuono G, Boccadoro M, Corradini P, Palumbo A. Bortezomib induction, reduced-intensity transplantation and lenalidomide consolidation-maintenance for myeloma: updated results. *Blood* 122:1376-83;2013
22. Sonneveld P, Verelst S, Lewis P, Gray-Schopfer V, Hutchings A, Nixon A, Petrucci MT. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. *Leukemia* 27:1959-69;2013
23. Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omedè P, Lerosé R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. Lenalidomide and low dose dexamethasone for newly diagnosed primary plasma cell leukemia. *Leukemia* 28:222-5;2013
24. Petrucci MT, Calabrese E, Levi A, Federico V, Ceccolini M, Rizzi R, Gozzetti A, Falco P, Lazzaro C, Martelli E, Boccadoro M, Lauria F, Liso V, Cavo M, Foa R. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. *Tumori* 99:193-202;2013

25. Dimopoulos MA, Palumbo A, Hajek R, Kropff M, Petrucci MT, Lewis P, Millar S, Zhang J, Mei J, Delforge M. Factors that influence health-related quality of life in newly diagnosed multiple myeloma patients aged ≥ 65 years treated with melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. *Leuk Lymphoma*. 55:1489-97;2014
26. Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M. Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. *J Clin Oncol* 32:634-40;2014
27. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. *Lancet Oncol* 15:333-42;2014
28. Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V, Musto P, Boccadifuoco L, Offidani M, Omedé P, Gentilini F, Ciccone G, Benevolo G, Genuardi M, Montefusco V, Oliva S, Caravita T, Tacchetti P, Boccadoro M, Sonneveld P, Palumbo A. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. *Blood* 124:63-9;2014
29. Palumbo A, Offidani M, Patriarca F, Petrucci MT, Cavo M. Bendamustine for the treatment of multiple myeloma in the first-line and relapsed-refractory settings: a review of the clinical trial data. *Leuk Lymphoma* 2:1-23;2014
30. Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Bladé J, Petrucci MT, Neben K, San Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JY. Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death. *J Clin Oncol*. 32:2173-80;2014
31. Soriani A, Iannitto ML, Ricci B, Fionda C, Malgarini G, Morrone S, Peruzzi G, Ricciardi MR, Petrucci MT, Cippitelli M, Santoni A. Reactive Oxygen Species- and DNA Damage Response-Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1. *J Immunol*. 193:950-60;2014
32. Caltagirone S, Ruggeri M, Aschero S, Gilestro M, Oddolo D, Gay F, Bringhen S, Musolino C, Baldini L, Musto P, Petrucci MT, Gaidano G, Passera R, Bruno B, Palumbo A, Boccadoro M, Omede' P. Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies. *Haematologica*. 99(10):1611-7; 2014
33. Petrucci MT, Finsinger P, Chisini M, Gentilini F. Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits. *Patient Prefer Adherence* 8:939-46;2014
34. Tacchetti P, Terragna C, Galli M, Zamagni E, Petrucci MT, Pezzi A, Montefusco V, Martello M, Tosi P, Baldini L, Peccatori J, Ruggieri M, Pantani L, Lazzaro A, Elice F, Rocchi S, Gozzetti A, Palumbo A, Cavaletti G, Cavo M. Bortezomib- and

- thalidomide-induced peripheral neuropathy in multiple myeloma: Clinical and molecular analyses of a phase 3 study. *Am J Hematol.* 89:1085-91; 2014
35. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovskiy E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omedé P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. *N Engl J Med* 371:895-905;2014
 36. Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, Sorino C, Ponzoni M, Bossi G, Federico V, La Rosa F, Ricciardi MR, Lesma E, De Meo PD, Castrignanò T, Petrucci MT, Pisani F, Chesi M, Bergsagel PL, Floridi A, Tonon G, Passananti C, Blandino G, Fanciulli M. Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy. *EMBO J.* 5:34;1214-30;2015
 37. Dimopoulos MA, Petrucci MT, Foa' R, Catalano J, Kropff M, Terpos E, Zhang J, Grote L, Jacques C, Palumbo A. Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival" as a clinical trial end-point. *Haematologica.* 100(8):e328-30; 2015
 38. Musto P, Simeon V, Grossi A, Gay F, Bringhen S, Larocca A, Guariglia R, Pietrantuono G, Villani O, D'Arena G, Cuomo C, Musto C, Morabito F, Petrucci MT, Offidani M, Zamagni E, Tacchetti P, Conticello C, Milone G, Palumbo A, Cavo M, Boccadoro M. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. *Stem Cell Res Ther* 17:6:64;2015
 39. Cifola I, Lionetti M, Pinatel E, Todoerti K, Mangano E, Pietrelli A, Fabris S, Mosca L, Simeon V, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Caravita T, Battaglia C, De Bellis G, Palumbo A, Musto P, Neri A. Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. *Oncotarget* 6:17543-58;2015
 40. Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, Petrucci MT, Ricciardi MR, Fuerst D, Amendola MG, Mytilineos J, Cerboni C, Paolini R, Cippitelli M, Santoni A. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. *J Immunol.* 15:195:736-48;2015
 41. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orłowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *J Clin Oncol* 33:2863-9;2015
 42. Fionda C, Abruzzese MP, Zingoni A, Cecere F, Vulpis E, Peruzzi G, Soriani A, Molfetta R, Paolini R, Ricciardi MR, Petrucci MT, Santoni A, Cippitelli M. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. *Oncotarget* 6:23609-30;2015
 43. Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F, Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P, Corradini P, Cavo M, Boccadoro M. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. *J Clin Oncol.* 33:3459-66;2015

44. Ponzetta A, Benigni G, Antonangeli F, Sciumè G, Sanseviero E, Zingoni A, Ricciardi MR, Petrucci MT, Santoni A, Bernardini G. Multiple myeloma impairs bone marrow localization of effector Natural Killer cells by altering the chemokine microenvironment. *Cancer Res.* 75:4766-77;2015
45. Cavo M, Pantani L, Pezzi A, Petrucci MT, Patriarca F, Di Raimondo F, Marzocchi G, Galli M, Montefusco V, Zamagni E, Gamberi B, Tacchetti P, Brioli A, Palumbo A, Sonneveld P. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. *Leukemia.* 29:2429-31;2015
46. Donnarumma P, Tarantino R, Rullo M, Grisaro A, Petrucci MT, Santoro A, Delfini R. Surgery for vertebral involvement in Multiple Myeloma. *J Neurosurg Sci.* Oct 16;2015
47. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. *Lancet Oncol.* 16:1617-29; 2015
48. Finsinger P, Grammatico S, Chisini M, Piciocchi A, Foà R, Petrucci MT. Clinical features and prognostic factors in solitary plasmacytoma. *Br J Haematol* 172:554-60; 2016
49. Gentilini F, Brunetti G, Finsinger P, Chisini M, Cartoni C, Foà R, Petrucci MT. Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program. *Leuk Lymphoma* 57:1716-8;2016
50. Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Montefusco V, Passera R, De Rosa L, Omedè P, Vincelli ID, Spada S, Carella AM, Ponticelli E, Derudas D, Genuardi M, Guglielmelli T, Nozzoli C, Aghemo E, De Paoli L, Conticello C, Musolino C, Offidani M, Boccadoro M, Sonneveld P, Palumbo A. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. *Leukemia.* 30:1320-6;2016
51. Leone C, Federico V, La Cesa S, Russo E, Di Stefano G, Finsinger P, Labriola R, Cruccu G, Petrucci MT, Truini A. An observational study assessing peripheral neuropathy related to multiple myeloma. *Neurol Sci. J* 37:1141-3;2016
52. Brunetti GA, Palumbo G, Morano GS, Baldacci E, Carmosino I, Annechini G, Talone R, Kiflom S, Mastrogiacomo G, Grammatico S, Chisini M, Costa A, Tendas A, Scaramucci L, Giovannini M, Niscola P, Petrucci MT, Cartoni C. Tapentadol PR for pain syndromes in real life patients with hematological malignancy. *Cardiovasc Hematol Agents Med Chem.* 14:68-74;2016
53. Ferretti A, De Angelis G, Petrucci MT. Severe clavicular disease in multiple myeloma. *Br J Haematol.* 73:820;2016
54. Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, Dimopoulos MA, Facon T. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or

Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. *J Clin Oncol.* 2016 Jun 20

55. Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górník S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). *Leukemia.* 2016 Jul 15